The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a more substantial loss